Abstract
Objectives There is a lack of circulating markers to predict disease outcome, therapy effect and monitoring for disease recurrence in endometrial cancer. The aim of this study was to explore whether plasma concentration of the inflammatory marker calprotectin is elevated in endometrial cancer and related to clinical parameters. Methods Calprotectin in EDTA-plasma samples from women with primary endometrial carcinoma ( n = 194), from healthy premenopausal ( n = 20) and postmenopausal ( n = 20) women was analyzed with ELISA. Results Median plasma calprotectin concentration was elevated in the patient group of endometrial cancer (3415 μg/L) as compared to the healthy premenopausal (832 μg/L) and postmenopausal groups (868 μg/L), both p < 0.001. Also, median calprotectin concentration was elevated in the endometrial cancer group as compared to women with invasive ovarian cancer, borderline ovarian tumor and benign ovarian tumors. Calprotectin plasma concentration correlated significantly with poor survival and high FIGO stage in endometrial carcinoma. Conclusion Calprotectin is elevated in plasma of women with endometrial carcinoma. Further studies are warranted to assess its possible value as a clinical tool for evaluating disease progression and relapse, as well as in monitoring treatment response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
